Praluent

Praluent Dosage/Direction for Use

alirocumab

Manufacturer:

sanofi-aventis

Distributor:

DKSH
Full Prescribing Info
Dosage/Direction for Use
Posology: The recommended starting dose of Praluent is 75 mg once every 2 weeks administered subcutaneously, since the majority of patients achieve sufficient LDL-C reduction with this dosage. An alternative starting dosage for patients who prefer less frequent dosing is 300 mg once every 4 weeks (monthly).
For patients receiving Praluent 75 mg every 2 weeks, measure LDL-C levels within 4 to 8 weeks of initiating Praluent. If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every 2 weeks. Reassess LDL-C within 4 to 8 weeks.
For patients receiving Praluent 300 mg every 4 weeks, measure LDL-C just prior to the next scheduled dose, since in some patients LDL-C can vary considerably between doses with this regimen. If LDL-C reduction is inadequate, the dosage may be adjusted to 150 mg every 2 weeks, starting the new dose on the next scheduled dosing date. Reassess LDL-C within 4 to 8 weeks.
If an every-2-week dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient's original schedule. If the missed dose is not administered within 7 days, instruct the patient to wait until the next dose on the original schedule.
If an every-4-week dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient's original schedule. If the missed dose is not administered within 7 days, instruct the patient to administer the dose, starting a new schedule based on this date.
Special populations: Paediatric population: The safety and efficacy of Praluent in children and adolescents less than 18 years of age have not been established. No data are available.
Elderly: No dose adjustment is needed for elderly patients.
Hepatic impairment: No dose adjustment is needed for patients with mild or moderate hepatic impairment. No data are available in patients with severe hepatic impairment.
Renal impairment: No dose adjustment is needed for patients with mild or moderate renal impairment. Limited data are available in patients with severe renal impairment (see Pharmacology: Pharmacokinetics under Actions).
Body weight: No dose adjustment is needed in patients based on weight.
Method of administration: Subcutaneous use.
Praluent is injected as a subcutaneous injection into the thigh, abdomen or upper arm.
To administer the 300 mg dose, give two 150 mg injections consecutively at two different injection sites.
It is recommended to rotate the injection site with each injection.
Praluent should not be injected into areas of active skin disease or injury such as sunburns, skin rashes, inflammation, or skin infections.
Praluent must not be co-administered with other injectable medicinal products at the same injection site.
The patient may either self-inject Praluent, or a caregiver may administer Praluent, after guidance has been provided by a healthcare professional on proper subcutaneous injection technique.
Precautions to be taken before handling: Praluent should be allowed to warm to room temperature prior to use (see Special precautions for disposal and other handling under Cautions for Usage).
Each pre-filled pen is for single use only.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in